A Study to Assess the Absorption of Apixaban (BMS-562247) Sprinkle Capsules Compared With Tablets in Healthy Volunteers
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 8/2/2018 |
| Start Date: | April 30, 2018 |
| End Date: | June 15, 2018 |
Relative Bioavailability of Apixaban (BMS-562247) 0.1 mg Sprinkle Capsules Compared With 0.5 mg Tablets in Healthy Participants
The purpose of this study is to evaluate the absorption of apixaban (BMS-562247) into the
bloodstream of healthy volunteers, when administered as sprinkle capsules compared to
tablets. Eligible participants will be randomly assigned to 1 of 2 treatment sequences and
will receive a single oral dose of apixaban twice during the course of the study.
bloodstream of healthy volunteers, when administered as sprinkle capsules compared to
tablets. Eligible participants will be randomly assigned to 1 of 2 treatment sequences and
will receive a single oral dose of apixaban twice during the course of the study.
Inclusion Criteria:
- Signed informed consent form.
- Healthy male and female participants determined by no clinically significant deviation
from normal in medical history, physical examination, 12-lead ECGs
(electrocardiograms), vital signs and clinical laboratory determinations.
- Women of childbearing potential (WOCBP) must have negative serum pregnancy tests
(performed at screening and Day 1), must not be breastfeeding, and must agree to
follow instructions for method(s) of contraception for duration of treatment with
study drug apixaban, and for a total of 33 days after last dose of apixaban.
- Males sexually active with women of childbearing potential must agree to follow
instructions for method(s) of contraception for duration of treatment with study drug
apixaban, and for a total of 93 days after the last dose of apixaban; and must be
willing to refrain from sperm donation during this time.
- Body mass index (BMI) of 18.0 to 30.0 kg/m², inclusive. Body mass index = weight
(kg)/[height(m)]².
Exclusion Criteria:
- History of chronic headaches (occurring 15 days or more a month) over the previous 3
months.
- History of gastroesophageal reflux disease, dyspepsia, protracted nausea, or chronic
diarrhea.
- History or evidence of abnormal bleeding or coagulation disorders, hypermenorrhea,
intracranial hemorrhage, or abnormal bleeding or coagulation disorders.
- Inability to comply with restrictions and prohibited treatments (e.g. women currently
taking hormonal contraception).
- Use of tobacco- or nicotine-containing products (e.g. cigarettes, pipes, cigars,
chewing tobacco, nicotine patches, nicotine lozenges, nicotine gum) within 6 months
prior to study drug administration.
- Donation of blood to a blood bank or in a clinical study (except screening or
follow-up visit) within 4 weeks of study drug administration (within 2 weeks for
plasma only).
Other protocol defined inclusion/exclusion criteria could apply.
We found this trial at
1
site
Click here to add this to my saved trials
